Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6-d-tryptophan-luteinizing Hormone-releasing Factor (pig)
2. Ay 25650
3. Ay-25650
4. Ay25650
5. Cl 118532
6. Cl-118532
7. Cl118532
8. D-trp-6-lh-rh
9. Decapeptyl
10. Decapeptyl Depot
11. Decapeptyl Lp
12. Decapeptyl Trimestral
13. Embonate, Triptorelin
14. Gnrh, Trp(6)-
15. Lhrh, Trp(6)-
16. Lhrh, Tryptophyl(6)-
17. Pamoate, Triptorelin
18. Trelstar
19. Trimestral, Decapeptyl
20. Triptorelin Embonate
21. Triptorelin Pamoate
22. Wy 42462
23. Wy-42462
24. Wy42462
1. 57773-63-4
2. Triptoreline
3. Arvekap
4. (d-trp6)-gnrh
5. Decapeptyl
6. Triptorelina
7. Triptorelinum
8. Trelstar
9. Triptodur
10. Diphereline
11. (6-d-tryptophan)luteinizing Hormone-releasing Hormone
12. Cl 118532
13. Cl-118532
14. Pglu-his-trp-ser-tyr-d-trp-leu-arg-pro-gly-nh2
15. Ay-25650
16. Luteinizing Hormone-releasing Factor (pig), 6-d-tryptophan
17. Cl 118,532
18. Chebi:63633
19. Wy 42462
20. Ay 25650
21. Pamorelin
22. Salvacyl
23. Trelstar Depot
24. 5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-tryptophyl-l-leucyl-l-arginyl-l-prolylglycinamide
25. Trelstar La
26. Luteinizing Hormone-releasing Factor (swine), 6-d-tryptophan-
27. Bim 21003
28. Wy 42422
29. Tryptorelin
30. Diferelin
31. D-tryptophan-lh-rh
32. Triptoreline [inn-french]
33. Triptorelinum [inn-latin]
34. Triptorelina [inn-spanish]
35. Trellasar
36. Moapar
37. Triptorelin [usan:inn:ban]
38. Decapeptyl Sr
39. Pamorelin La
40. Unii-9081y98w2v
41. Triptorelin (swine)
42. Wy-42462
43. D-trp6-lhrh
44. Debio-8206
45. Triptorelin (usan/inn)
46. (d-trp6)-lh-rh
47. Gtpl1177
48. Schembl5079698
49. Chembl1201334
50. Dtxsid2048375
51. Schembl22289009
52. Hms2090c17
53. Ex-a3857
54. Bim-21003
55. Akos030213249
56. 9081y98w2v
57. Cs-5745
58. Db06825
59. Ncgc00167301-01
60. Ncgc00167301-02
61. As-71149
62. Bn-52014
63. Hy-12551
64. 73t634
65. C75704
66. D06247
67. [d-trp6]-lh-rh, >=97% (hplc), Powder
68. Ab01275488-01
69. A936467
70. Pglu-his-trp-ser-tyr-d-trp-leu-arg-pro-glynh2
71. Q1992452
72. (s)-1-((3s,6s,9s,12s,15r,18s,21s)-3-((1h-imidazol-5-yl)methyl)-6,15-bis((1h-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((s)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-n-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide
73. Glycinamide, 5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-tryptophyl-l-leucyl-l-arginyl-l-prolyl-
Molecular Weight | 1311.4 g/mol |
---|---|
Molecular Formula | C64H82N18O13 |
XLogP3 | -0.3 |
Hydrogen Bond Donor Count | 17 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 33 |
Exact Mass | 1310.63087474 g/mol |
Monoisotopic Mass | 1310.63087474 g/mol |
Topological Polar Surface Area | 490 Ų |
Heavy Atom Count | 95 |
Formal Charge | 0 |
Complexity | 2710 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Trelstar |
PubMed Health | Triptorelin (Injection) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | TRELSTAR is a white to slightly yellow lyophilized cake. When reconstituted, TRELSTAR has a milky appearance. It contains a pamoate salt of triptorelin, a synthetic decapeptide agonist analog of gonadotropin releasing hormone (GnRH). The chemical... |
Active Ingredient | Triptorelin pamoate |
Dosage Form | Injectable |
Route | Intramuscular |
Strength | eq 11.25mg base/vial; eq 3.75mg base/vial; eq 22.5mg base/vial |
Market Status | Prescription |
Company | Watson Labs |
2 of 2 | |
---|---|
Drug Name | Trelstar |
PubMed Health | Triptorelin (Injection) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | TRELSTAR is a white to slightly yellow lyophilized cake. When reconstituted, TRELSTAR has a milky appearance. It contains a pamoate salt of triptorelin, a synthetic decapeptide agonist analog of gonadotropin releasing hormone (GnRH). The chemical... |
Active Ingredient | Triptorelin pamoate |
Dosage Form | Injectable |
Route | Intramuscular |
Strength | eq 11.25mg base/vial; eq 3.75mg base/vial; eq 22.5mg base/vial |
Market Status | Prescription |
Company | Watson Labs |
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
FDA Label
For the synchronisation of ovulation in weaned sows to enable a single fixed-time artificial insemination.
The first administration of triptorelin is followed by a transient surge of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol,and testosterone. The time, peak and decline of testosterone in the body varies depending on the dose administered. This initial surge is often responsible for worsening of prostate cancer symptoms such as urethral or bladder outlet obstruction, bone pain, spinal cord injury and hematuria in the early stages. A sustained decrease in FSH and LH, and significant reduction of testicular steroidogenesis is usually seen 2-4 weeks post-initiation of therapy. This result is a reduction of serum testosterone to levels which are typically seen in surgically castrated men. Ultimately, tissues and functions that require these hormones become inactive. The effects of triptorelin can usually be reversed once the drug is discontinued.
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Luteolytic Agents
Chemical compounds that cause LUTEOLYSIS or degeneration of the CORPUS LUTEUM. (See all compounds classified as Luteolytic Agents.)
QH01CA97
L - Antineoplastic and immunomodulating agents
L02 - Endocrine therapy
L02A - Hormones and related agents
L02AE - Gonadotropin releasing hormone analogues
L02AE04 - Triptorelin
Absorption
Following IV administration of triptorelin, triptorelin is completely absorbed.
Route of Elimination
Elimination of triptorelin involves both the kidneys and the liver.
Volume of Distribution
After a single IV dose of 0.5mg, the volume of distribution of triptorelin peptide in healthy males was 30 - 33L.
Clearance
In healthy male volunteers, total clearance of triptorelin was 211.9 mL/min.
The metabolism of triptorelin in humans is not well understood; however, metabolism likely does not involve hepatic enzymes such as cytochrome P450. Whether or not triptorelin affects, or how it affects other metabolizing enzymes is also poorly understood. Triptorelin has no identified metabolites.
The pharmacokinetics of triptorelin follows a 3 compartment model. The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.
Triptorelin is a synthetic agonist analog of gonadotropin releasing hormone (GnRH). Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone.
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0006
Start Marketing Date : 2006-06-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62788-437
Start Marketing Date : 2010-10-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-956
Start Marketing Date : 2017-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-288
Start Marketing Date : 2001-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (11.25mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-715
Start Marketing Date : 2000-06-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (3.75mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 59149-006
Start Marketing Date : 2023-02-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (500g/500g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71161-103
Start Marketing Date : 2000-06-15
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-105
Start Marketing Date : 2010-03-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-104
Start Marketing Date : 2001-06-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-106
Start Marketing Date : 2017-09-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Brand Name: Trelstar
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 01, 2022
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Debiopharm
Deal Size : Undisclosed
Deal Type : Partnership
Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa
Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...
Product Name : Trelstar
Product Type : Peptide
Upfront Cash : Undisclosed
February 01, 2022
Details:
The net proceeds will be allocated to advancing the company’s pipeline, including FP-014 (triptorelin), a ready-to-use, long-acting injectable developed for the treatment of prostate cancer.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Brand Name: FP-014
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Undisclosed
Deal Size: $42.1 million Upfront Cash: Undisclosed
Deal Type: Financing December 04, 2024
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $42.1 million
Deal Type : Financing
Foresee Pharmaceuticals Announces Completion of US$42.1 Million Financing
Details : The net proceeds will be allocated to advancing the company’s pipeline, including FP-014 (triptorelin), a ready-to-use, long-acting injectable developed for the treatment of prostate cancer.
Product Name : FP-014
Product Type : Peptide
Upfront Cash : Undisclosed
December 04, 2024
Details:
Debio 4326 is a unique injectable, biodegradable 12-month extended-release formulation of triptorelin, being developed for pediatric participants for central precocious puberty.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Endocrinology Brand Name: Debio 4326
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2024
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Patients Dosed in Phase III Trial of Debio 4326 for Central Precocious Puberty
Details : Debio 4326 is a unique injectable, biodegradable 12-month extended-release formulation of triptorelin, being developed for pediatric participants for central precocious puberty.
Product Name : Debio 4326
Product Type : Peptide
Upfront Cash : Not Applicable
September 09, 2024
Details:
Dexa Medica’s nation-wide launch and distribution of triptorelin, as Debiopharm’s exclusive Indonesian licensee, will help patients in the region gain access to the pain-relieving benefits of hormone suppression with Pamorelin®.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Pamorelin
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2021
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Dexa Medica’s nation-wide launch and distribution of triptorelin, as Debiopharm’s exclusive Indonesian licensee, will help patients in the region gain access to the pain-relieving benefits of hormone suppression with Pamorelin®.
Product Name : Pamorelin
Product Type : Large molecule
Upfront Cash : Undisclosed
October 07, 2021
Details:
The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Brand Name: Trelstar
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Verity Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2020
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.
Product Name : Trelstar
Product Type : Large molecule
Upfront Cash : Undisclosed
June 09, 2020
Details:
The agreement grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Knight Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 08, 2020
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Knight Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada
Details : The agreement grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
January 08, 2020
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Trelstar LA 3,75 mg
Dosage Form : POI
Dosage Strength : 3.75mg
Packaging : 2X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Trelstar LA 11,25 mg
Dosage Form : POI
Dosage Strength : 11.25mg
Packaging : 2X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Trelstar LA 22,5 mg
Dosage Form : POI
Dosage Strength : 22.5mg
Packaging : 2X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Switzerland
Brand Name : Pamorelin LA
Dosage Form : Trockensub
Dosage Strength : 11.25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Salvacyl
Dosage Form : Trockensub
Dosage Strength : 11.25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Gonapeptyl
Dosage Form : Injection fluid, resolution
Dosage Strength : 0.1 mg/ml
Packaging : Finish filled syringe
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : Decapeptyl
Dosage Form : Tryptoreline 3,75Mg 1 Unit Parenteral Use
Dosage Strength : 1 vial IM 3.75 mg + 1 ampoule solv 2 ml + 1 syringe
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Australia
Brand Name : Diphereline
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Sweden
Brand Name : Moapar
Dosage Form : PULVER OCH VÄTSKA TILL INJEKTIONSVÄTSKA
Dosage Strength : 11,25 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Pamorelin
Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Dosage Strength : 3.75 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Diphereline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Diphereline, including repackagers and relabelers. The FDA regulates Diphereline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Diphereline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Diphereline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Diphereline supplier is an individual or a company that provides Diphereline active pharmaceutical ingredient (API) or Diphereline finished formulations upon request. The Diphereline suppliers may include Diphereline API manufacturers, exporters, distributors and traders.
click here to find a list of Diphereline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Diphereline DMF (Drug Master File) is a document detailing the whole manufacturing process of Diphereline active pharmaceutical ingredient (API) in detail. Different forms of Diphereline DMFs exist exist since differing nations have different regulations, such as Diphereline USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Diphereline DMF submitted to regulatory agencies in the US is known as a USDMF. Diphereline USDMF includes data on Diphereline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Diphereline USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Diphereline suppliers with USDMF on PharmaCompass.
A Diphereline written confirmation (Diphereline WC) is an official document issued by a regulatory agency to a Diphereline manufacturer, verifying that the manufacturing facility of a Diphereline active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Diphereline APIs or Diphereline finished pharmaceutical products to another nation, regulatory agencies frequently require a Diphereline WC (written confirmation) as part of the regulatory process.
click here to find a list of Diphereline suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Diphereline as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Diphereline API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Diphereline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Diphereline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Diphereline NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Diphereline suppliers with NDC on PharmaCompass.
Diphereline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Diphereline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Diphereline GMP manufacturer or Diphereline GMP API supplier for your needs.
A Diphereline CoA (Certificate of Analysis) is a formal document that attests to Diphereline's compliance with Diphereline specifications and serves as a tool for batch-level quality control.
Diphereline CoA mostly includes findings from lab analyses of a specific batch. For each Diphereline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Diphereline may be tested according to a variety of international standards, such as European Pharmacopoeia (Diphereline EP), Diphereline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Diphereline USP).
LOOKING FOR A SUPPLIER?